Neuroprotective Agents: Seventh International Conference, Volume 1053

As life expectancy has increased, so has the incidence of neurodegenerative diseases, particularly those associated with aging. Contributing to increased life expectancy is increased survival following brain injury, stroke, and procedures such as heart surgery, but these events can impair neurological function.
The wide range of contributions to this volume, from a detailed paper on the use of gene therapy in combination with hypothermia for the treatment of cerebral ischemia to a comprehensive poster describing the role of anesthetic agents in neurotoxicity during development and senescence, illustrate the scientific scope presented.
Contributions from clinical and basic science researchers from many disciplines address various approaches to providing neuroprotection. The clinical focus is on the complexity of neuroprotection, the need for understanding the time–course effects of hypoxia/ischemia, and the need for combinational and time–course applications of multiple therapies. New technologies are introduced for describing both the insult and the treatment necessary for neuroprotection, including gene expression assays (genomics) and gene therapy.
Several chapters are devoted to the examination of the predictive value of models for outcome measures in clinical ischemic stroke neuroprotective trials. The need to move from in vitro models to more predictive in vivo approaches with the use of pharmacokinetics is addressed. Other chapters emphasize the role of endogenous agents such as nitric oxide, melatonin, L–carnitine, and estrogens in acute and chronic neural injury and therapy.
NOTE: Annals volumes are available for sale as individual books or as a journal. For information on institutional journal subscriptions, please visit www.blackwellpublishing.com/nyas.
ACADEMY MEMBERS: Please contact the New York Academy of Sciences directly to place your order (www.nyas.org). Members of the New York Academy o f Science receive full–text access to the Annals online and discounts on print volumes. Please visit www.nyas.org/membership/main.asp for more information about becoming a member.

Spis treści:
Preface: William Slikker, Jr., Russell J. Andrews, and Bruce Trembly.
.
Part I: The Human Experience of Neuroprotection:.
1. Neuroprotection Trek—The Next Generation: The Measurement Is the Message: Russell J. Andrews.
2. Protective Effect of Neuromonitoring during Cardiac Surgery: Harvey L. Edmonds, Jr.
3. Neuropsychiatric Alterations in MDMA Users: Preliminary Findings: Ronald I. Herning, Warren Better, Kimberly Tate, And Jean L. Cadet.
4. Intraoperative Monitoring during Aneurysm Surgery as a Neuroprotective Activity with Reference to Evoked Potential and Microvascular Doppler Techniques: Karl E. Sanzenbacher.
5. Panel of Biomarkers Predicts Stroke: D T Laskowitz, R Blessing, J Floyd, W D White, And J R Lynch.
6. Evaluating Neuroprotective Agents in Coronary Artery Bypass Surgery: Stanton Newman.
7. Questions and Answers: Session I: The Human Experience of Neuroprotection.
.
Part II: Mechanisms of Neuroprotection (1):.
8. Delineating and Understanding Cerebellar Neuroprotective Pathways: Potential Implication for Protecting the Cortex: Xuan Wu, Xueying Jiang, Ann M. Marini, And Robert H. Lipsky.
9. A Role for Calpain in Optic Neuritis: M Kelly Guyton, Eric A. Sribnick, Swapan K. Ray, And Naren L. Banik.
10. Activation of Neuroprotective Pathways by Metabotropic Group I Glutamate Receptors: A Potential Target for Drug Discovery?: Andrius Baskys, Liwei Fang, And Ildar Bayazitov.
11. Antiapoptotic and Anti–inflammatory Mechanisms of Heat–Shock Protein Protection: Midori A. Yenari, Jialing Liu, Zhen Zheng, Zinaida S. Vexler, Jong Eun Lee, And Rona G. Giffard.
12. Neuroprotection by NGF in the PC12 In Vitro OGD Model: Involvement of Mitogen–Activated Prot ein Kinases and Gene Expression: Rinat Tabakman, Hao Jiang, Iris Shahar, Hadar Arien–Zakay, Robert A. Levine, And Philip Lazarovici.
13. Role of Peroxynitrite in Methamphetamine–Induced Dopaminergic Neurodegeneration and Neuroprotection by Antioxidants and Selective NOS Inhibitors: Syed F. Ali, Syed Z. Imam, And Yossef Itzhak.
14. Questions and Answers: Session II: Mechanisms of Neuroprotection (1).
.
Part III: Neuroprotection in Inflammation–Related Neurodegenerative Diseases:.
15. Microglial NADPH Oxidase Mediates Leucine Enkephalin Dopaminergic Neuroprotection: Liya Qin, Yuxin Liu, Xun Qian, Jau–Shyong Hong, And Michelle L. Block.
16. Effect of Neuroprotective Drugs on Gene Expression in G93A/SOD1 Mice: Sheila Ignacio, Dan H. Moore, Andrew P. Smith, And Nancy M. Lee.
17. Brain Response to Injury and Neurodegeneration: Endogenous Neuroprotective Signaling: Nicolas G. Bazan, Victor L. Marcheselli, And Kasie Cole–Edwards.
18. Early Effects of Modulating Nuclear Factor–B Activation on Traumatic Spinal Cord Injury in Rats: Octavio Jiménez–Garza, Javier Camacho, Antonio Ibarra, Angelina Martínez, And Gabriel Guízar–Sahagún.
19. Role of Inflammation in the Pathogenesis of Parkinson′s Disease: Models, Mechanisms, and Therapeutic Interventions: Jau–Shyong Hong.
.
Part IV: Role of Carnitines and Other Agents in Neuroprotection:.
20. Mechanisms of Ischemic Neuroprotection by Acetyl–l–carnitine: Santina A. Zanelli, Nina J. Solenski, Robert E. Rosenthal, and Gary Fiskum.
21. Identification of Rat Hippocampal mRNAs Altered by the Mitochondrial Toxicant, 3–NPA: Beata D. Przybyla–Zawislak, Brett T. Thorn, Syed F. Ali, Richard A. Dennis, Antonino Amato, Ashraf Virmani, And Zbigniew K. Binienda.
22. l–Carnitine and Neuroprotection in the Animal Model of Mitochondrial Dysfunction: Zbigniew Binienda, Beata PrzybylaR 11;Zawislak, Ashraf Virmani, And Larry Schmued.
23. Effects of Metabolic Modifiers Such as Carnitines, Coenzyme Q10, and PUFAs against Different Forms of Neurotoxic Insults: Metabolic Inhibitors, MPTP, and Methamphetamine: Ashraf Virmani, Franco Gaetani, And Zbigniew Binienda.
24. Questions and Answers: Session IV: Role of Carnitines and Other Agents in Neuroprotection.
.
Part V: Neuroprotective Approaches and Models:.
25. The Antiapoptotic Actions of Mood Stabilizers: Molecular Mechanisms and Therapeutic Potentials: De–Maw Chuang.
26. Circulatory Arrest as a Model for Studies of Global Ischemic Injury and Neuroprotection: Lars Wiklund, Hari Shanker Sharma, and Samar Basu.
27. Possible Neuroprotective Mechanism of Human Neuroglobin: Keisuke Wakasugi, Chihiro Kitatsuji, And Isao Morishima.
28. The Impact of Aging, Dietary Restriction, and Glucocorticoids on ApoE Gene Expression in Rat Brain: S Ruzdijic, M Perovic, A Mladenovic, D Milanovic, L Rakic, S Petanceska, And S Kanazir.
29. Questions and Answers: Session V: Neuroprotective Approaches and Models.
.
Part VI: Neuroprotective Agents and Mechanisms.
30. Saposin C: Neuronal Effect and CNS Delivery by Liposomes: Zhengtao Chu, Ying Sun, Chia Yi Kuan, Gregory A. Grabowski, And Xiaoyang Qi.
31. Brain–Derived Neurotrophic Factor Is Neuroprotective against Human Immunodeficiency Virus–1 Envelope Proteins: Alessia Bachis And Italo Mocchetti.
32. Nicotinamide Modulates Energy Utilization and Improves Functional Recovery from Ischemia in the In Vitro Rabbit Retina: Diamond Tam, Majestic Tam, And Kenneth I. Maynard.
33. Mechanisms of Disease: Motoneuron Disease Aggravated by Transgenic Expression of a Functionally Modified AMPA Receptor Subunit: Rohini Kuner, Anthony J. Groom, Gerald Müller, Hans–Christian Kornau, Vanya Stefovska, Iris Bresink, Bettina Hartmann, Karsten Tschauner, Stefan Waibel, Albert C. Ludolph, Chrysanthy Ikonomidou,